Small Cell Lung Cancer News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

The role of brigatinib in crizotinib-resistant non-small cell lung cancer - Dove Medical Press



The role of brigatinib in crizotinib-resistant non-small cell lung cancer 
Dove Medical Press
Abstract: Despite the advances in new targeted therapies in ALK positive population, most patients progress under ALK inhibitors within first 2 years; being the brain the most frequent site of relapse. ALK mutations, in ~30% of patients, are the main ...

 


Small-Cell Lung Cancer (SCLC) Market Spotlight 2017: Pfizer Carried 8 Phase III Trials, Followed by GlaxoSmithKline ... - GlobeNewswire (press release)



Small-Cell Lung Cancer (SCLC) Market Spotlight 2017: Pfizer Carried 8 Phase III Trials, Followed by GlaxoSmithKline ... 
GlobeNewswire (press release)
Licensing and asset acquisition activity involving SCLC drugs has been weak during 201217, with only nine deals over this time period. The $356m license agreement between CytRx and NantCell for the exclusive rights to develop and market aldoxorubicin ...

and more » 


FDA Expands Gilotrif Indication for Non?Small-Cell Lung Cancer - P&T Community



PharmaTimes
 
FDA Expands Gilotrif Indication for Non?Small-Cell Lung Cancer 
P&T Community
The FDA has approved a supplemental new drug application (sNDA) for afatinib (Gilotrif, Boehringer Ingelheim) for the first-line treatment of patients with metastatic non?small-cell lung cancer (NSCLC) whose tumors have nonresistant epidermal growth ...
FDA Approves Expanded Indication for Gilotrif in NSCLC Monthly Prescribing Reference
US expands scope of BI's lung cancer drug Gilotrif PharmaTimes
FDA Expands Indication of Afatinib to Include EGFR-Mutated Lung Cancer Specialty Pharmacy Times
Markets Insider 
all 6 news articles » 


First-line Keytruda plus chemotherapy improves OS, PFS in non-small cell lung cancer - Healio



Drug Discovery & Development
 
First-line Keytruda plus chemotherapy improves OS, PFS in non-small cell lung cancer 
Healio
In the phase 3 KEYNOTE-189 trial ? which included 614 patients with advanced or metastatic nonsquamous non-small cell lung cancer, regardless of PD-L1 expression, who had no EGFR or ALK mutations and had not previously received systemic therapy for ...
Merek's KEYTRUDA Improved Overall Survival in Patients with Non-small Cell Lung Cancer Drug Discovery & Development
Frontline Pembrolizumab Combo Improves Survival in Phase III ... OncLive
Merck: Elucidating The Ramifications Of The Recent Keynote Findings Seeking Alpha
Motley Fool  -24/7 Wall St. 
all 14 news articles » 


Merck shares jump after combination trial shows Keytruda extends lung cancer survival - CNBC



CNBC
 
Merck shares jump after combination trial shows Keytruda extends lung cancer survival 
CNBC
Roche's shares fell 2.5 percent on Tuesday, while shares of Bristol-Myers dipped nearly 2 percent in U.S. premarket trading. The Merck study tested a cocktail of Keytruda, Eli Lilly's Alimta and a standard chemotherapy as an initial treatment for ...
Positive Keytruda lung cancer data sends Merck shares up 6 percent Reuters
UPDATED: Merck's Keytruda combo wows again, acing PhIII overall survival goal for lung cancer early Endpoints News
Merck Is Latest to Tout Success as Lung Cancer Drug Combos Plow Forward Xconomy
TheStreet.com  -P&T Community  -Zacks.com  -SEC.gov 
all 225 news articles » 


NICE shoots down Pfizer's Xalkori in ROS1-positive patients, inviting a CDF proposal instead - FiercePharma



FiercePharma
 
NICE shoots down Pfizer's Xalkori in ROS1-positive patients, inviting a CDF proposal instead 
FiercePharma
?Using crizotinib in the Cancer Drugs Fund would provide important data? that right now NICE feels is lacking in untreated patients, it wrote. NICE will also take public comments until Feb. 7, ahead of a second appraisal meeting on Feb. 21. Pfizer, for ...

 


Patient Voices: Lung Cancer - New York Times



New York Times
 
Patient Voices: Lung Cancer 
New York Times
Nancy Gatschet, a banker, found out she had small cell lung cancer in 2006 ? a year after she quit smoking. After further tests, Ms. Gatschet was told that her cancer had begun to spread into her lymph nodes, so it was unclear whether she should be ...

 


Levy Discusses Remaining Questions in NSCLC as Field Awaits Frontline Osimertinib Approval - Targeted Oncology



Targeted Oncology
 
Levy Discusses Remaining Questions in NSCLC as Field Awaits Frontline Osimertinib Approval 
Targeted Oncology
While the FDA approval of osimertinib (Tagrisso) for patients with EGFR T790M?positive non?small cell lung cancer (NSCLC) who progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy has made a significant impact in the field of lung cancer ...

 


After being diagnosed with cancer, Myrtle Beach acts as sanctuary for W.Va. woman - Myrtle Beach Sun News



Myrtle Beach Sun News
 
After being diagnosed with cancer, Myrtle Beach acts as sanctuary for W.Va. woman 
Myrtle Beach Sun News
Patterson, who lives in Huntingdon, W.Va., was diagnosed with stage four small cell lung cancer in early November. After going through chemotherapy treatments, friends decided to put together a trip to Myrtle Beach where Patterson can reunite with old ...

 


Friends, family rally around mother of 8 who has cancer | Thousand ... - Thousand Oaks Acorn



Thousand Oaks Acorn
 
Friends, family rally around mother of 8 who has cancer | Thousand ... 
Thousand Oaks Acorn
DEEPLY LOVED?Beth Quinn at the wedding of her daughter Lexa in December. Quinn attended the wedding a week after learning she'd been diagnosed with stage 4 lung cancer. Courtesy photo. A week before her daughter Lexa's December wedding, Beth Quinn ...

and more »